Hims & Hers Health (HIMS) News Today

Hims & Hers Health logo
$16.18 -0.87 (-5.07%)
As of 12:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Why Is Hims & Hers Health Dropping Today?

Hims & Hers Health, Inc. (NYSE: HIMS) faces a mixed set of signals: its new peptide offering could broaden its telehealth business, but questions about treatment evidence and recent insider sales may weigh on investor sentiment.

  • Positive Sentiment: Hims & Hers launched Peptides+, adding five compounded treatments—including sermorelin, glutathione and NAD+—to its personalized-health platform. The expansion could create new services and revenue opportunities. Hims & Hers Peptides+ announcement
  • Neutral Sentiment: The initial peptide treatments are compounded and not FDA-approved. The company acknowledged that more research is needed on efficacy, leaving uncertainty around demand and potential regulatory or reputational risks. CNBC report on peptide treatments
  • Negative Sentiment: Two insiders sold shares: CFO Oluyemi Okupe sold 3,518, while Deborah Autor sold 23,828. Both transactions were under pre-arranged Rule 10b5-1 plans, which may reduce their significance as a signal, but the sales could still concern investors. Insider transaction report
  • Negative Sentiment: Recent quarterly results came in below expectations: earnings per share were $0.03 versus $0.06 expected, and revenue was slightly short of consensus. Revenue still grew 48.6% year over year, but the misses add to concerns about execution. Hims & Hers financial results
Posted 50m agoAI Generated. May Contain Errors.

Hims & Hers Health Latest News

Hims & Hers launches Peptides+ as federal restrictions ease
Hims Is Getting into Peptides
Hims & Hers Health (NYSE:HIMS) CFO Sells 3,518 Shares of Stock
Hims & Hers Stock Fell 32% As Profit Slipped
Hims & Hers: Further Expanding Internationally
What Hims & Hers Health Investors Missed Before The Fall
Hims & Hers logo overlaid on medical syringes, measuring tape, and financial charts symbolizing telehealth weight-loss market growth.
Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
Hims & Hers stock sank after a Q3 earnings and revenue miss, lower EBITDA guidance, subscriber declines, and an expanding FTC lawsuit over privacy and billing practices.
Hims & Hers: Three Big Sacrifices
Hims & Hers Health (HIMS) Receives a Hold from Morgan Stanley
Hims & Hers Q3 Earnings Miss Estimates, Gross Margin Down
Hims & Hers Health Stock Falls 16%
Comparing Cigna Group (NYSE:CI) & Hims & Hers Health (NYSE:HIMS)
Hims & Hers Health: Don't Nitpick Quarterly Results
Top Medical Stocks To Follow Now - November 10th

Hims & Hers Health Media Mentions By Week

Hims & Hers Health Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

HIMS
News Sentiment
▼
-0.19

0.37
▲
Average
Healthcare
News Sentiment

Hims & Hers Health News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

HIMS Articles
This Week
▼
25

8
▲
HIMS Articles
Average Week

Hims & Hers Health Trends on MarketBeat

This week vs. last week
New Followers
2
Searches
7
-65%
Page Views
5,147
-6%
Get Hims & Hers Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Hims & Hers Health dated 11/19/2026.
From Our Partners